Intriguingly, although no differential impact was observed in classical BC subtypes, KDM1B combined with IFN-I signature or with stemness signature positively associated with dismal prognosis in HER2 negative (HER2neg) but not in HER2 positive (HER2pos) tumors (Extended Data Fig. 7c,d). Here, ERBB2 is linked to breast cancer.